# Nuclide record nct07259213 (trial). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/trials/nct07259213/>
  a schema:MedicalTrial ;
  nuclide:kind "trial" ;
  schema:identifier "nct07259213", "NCT07259213" ;
  schema:name "A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC"@en ;
  schema:description "A phase 1/2 trial of 161Tb RAD402 in prostate cancer, run by Radiopharm Theranostics, Ltd, now recruiting."@en ;
  schema:url <https://nuclide.cc/trials/nct07259213/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07259213> ;
  nuclide:status "recruiting" ;
  nuclide:tag "pipeline", "ctgov-ingest" ;
  nuclide:phase "1/2" ;
  nuclide:related <https://nuclide.cc/isotopes/tb-161/> ;
  nuclide:indications <https://nuclide.cc/indications/prostate/> ;
  nuclide:companies <https://nuclide.cc/companies/radiopharm-theranostics/> .